Evidence map›Paper›PMID 27534951›Full record

ArticleClinical and experimental nephrology2017

Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.

Kota Takahashi, Kazuhide Saito, Shiro Takahara, Shohei Fuchinoue, Takashi Yagisawa, Atsushi Aikawa, Yoshihiko Watarai, Norio Yoshimura, Kazunari Tanabe, Kunio Morozumi and 2 more

Abstract readClinical StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  3. Article
  4. Article
  5. C1q Binding Ability for Prior Risk Assessment of Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kota TakahashiNiigata Organ Transplant Foundation, Niigata, Japan. takahashi-kouta@image.ocn.ne.jp.
Kazuhide SaitoDivision of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Shiro TakaharaDepartment of Advanced Technology for Transplantation, Osaka University Graduate School of Medicine, Osaka, Japan.
Shohei FuchinoueDepartment of Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Takashi YagisawaSurgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Tochigi, Japan.
Atsushi AikawaDepartment of Nephrology, Toho University, Tokyo, Japan.
Yoshihiko WataraiTransplant Surgery, Nagoya Daini Red Cross Hospital, Aichi, Japan.
Norio YoshimuraDepartment of Organ Transplant and General Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kazunari TanabeDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Kunio MorozumiDepartment of Nephrology, Masuko Memorial Hospital, Aichi, Japan.
Motohide ShimazuDepartment of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
IDEC-C2B8 ABO-I KTx Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDeceased organ donations are rare in Japan, with most kidney transplants performed from a limited number of living donors. Researchers have thus developed highly successful ABO-incompatible transplantation procedures, emphasizing preoperative desensitization and postoperative immunosuppression. A recent open-label, single-arm, multicenter clinical study prospectively examined the efficacy and safety of rituximab/mycophenolate mofetil desensitization in ABO-incompatible kidney transplantation without splenectomy.

methodsMycophenolate mofetil and low dose steroid were started 28 days pretransplant, followed by two doses of rituximab 375 mg/m

resultsEighteen patients received rituximab and underwent ABO-incompatible kidney transplantation. CD19-positive peripheral B cell count decreased rapidly after the first rituximab infusion and recovered gradually after week 36. The desensitization protocol was tolerable, and most rituximab-related infusion reactions were mild. No anti-A/B antibody-mediated rejection occurred with this series. One patient developed anti-HLA antibody-mediated rejection (Banff 07 type II) on day 2, which was successfully managed. Patient and graft survival were both 100 % after 1 year.

conclusionOur desensitization protocol was confirmed to be clinically effective and with acceptable toxicities for ABO-I-KTx (University Hospital Medical Information Network Registration Number: UMIN000006635).

Indexed as

Kidney TransplantationABO Blood-Group SystemAdolescentAdultAgedBlood Group IncompatibilityDesensitization, ImmunologicDrug Administration ScheduleDrug Therapy, CombinationFemaleGraft RejectionGraft SurvivalHistocompatibilityHLA AntigensHumansImmunosuppressive AgentsABO Blood-Group SystemHLA AntigensImmunosuppressive AgentsIsoantibodiesRituximabABO incompatibilityAntibody-mediated rejectionDesensitization therapyKidney transplantationPlasma exchangeRituximab

Identifiers

PMID27534951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.